Popular GH Peptide Protocols: Tesamorelin vs CJC-1295+Ipamorelin vs Sermorelin vs MK-677

Summary

There is no single 'best' GH peptide — the right choice depends on your goals, tolerance for injection, budget, and how much you care about FDA approval. Tesamorelin is the only currently FDA-approved GH secretagogue, with Phase III evidence in HIV-associated visceral adiposity. That evidence is why it sits at the top of regulatory trust but also what limits it — daily injection, high brand pricing, and a narrow approved indication. For patients who need FDA-backed therapy or who specifically have visceral fat to reduce, it's the evidence leader. The CJC-1295 + Ipamorelin combination is the most popular biohacking GH protocol for a reason: the two peptides act on complementary pathways (GHRH receptor + ghrelin receptor), producing a synergistic GH response greater than either alone. Ipamorelin's selectivity — minimal cortisol, prolactin, or appetite effects — makes it far better tolerated than older GHRPs. The combination is not FDA-approved but is routinely compounded with clinician oversight. The main nuance is CJC-1295 with DAC (long-acting) vs without DAC (short-acting); the long-acting version produces sustained GH elevation that departs from the physiologic pulsatile pattern some clinicians prefer to preserve. Sermorelin is the historical option. It mimics endogenous GHRH almost exactly, produces gentle physiologic GH restoration, and has the longest clinical track record of the injectables. Its main drawback is the 11–16 minute half-life — it requires strict daily dosing before bed to align with natural GH pulses. It was FDA-approved until 2008 (withdrawn for commercial reasons, not safety) and is now available through compounding. MK-677 (ibutamoren) is the oral option and the cheapest, making it tempting for new users. The problems are real: appetite stimulation is pronounced enough to be a frequent drop-off reason, insulin sensitivity can decline with chronic use, and a congestive heart failure trial was halted for excess mortality in elderly patients (though this was a specific population, not healthy users). Merck abandoned development. For healthy adults it's used off-label — oral convenience traded against less favorable side effects than the injectables. The decision tree most clinicians follow: if you need proven efficacy and can tolerate cost and injections, start with Tesamorelin. If you want sustained GH elevation and are comfortable with injectable compounded therapy, CJC-1295 + Ipamorelin is the mainstream choice. If you want the gentlest, most physiologic option with the longest clinical history, Sermorelin. If oral convenience matters more than the metabolic trade-offs, MK-677. All four should be used under clinician guidance with IGF-1 monitoring, and none should be used without a clear goal and baseline labs.